This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Flaker, G. C. Search for Related Content PubMed PubMed Citation Articles by Flaker, G. C.

Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations

Greg C. Flaker, MD, FACC^*, J. Wayne Warnica, MD, FACC, Frank M. Sacks, MD, Lemuel A. Moyé, MD, PhD, Barry R. Davis, MD, PhD, Jean L. Rouleau, MD^||, Richard R. Webel, MD^*, Marc A. Pfeffer, MD, PhD, Eugene Braunwald, MD for the Cholesterol and Recurrent Events CARE Investigators^**

^* University of Missouri, Columbia, Missouri, USA
Foothills Hospital, Calgary, Alberta, Canada
University of Texas School of Public Health, Houston, Texas, USA
Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
^|| Montreal Heart Institute, Montreal, Quebec, Canada

View larger version (13K): [in a new window]   Figure 1 Primary event rate in PTCA-treated patients on pravastatin or placebo.

View larger version (13K): [in a new window]   Figure 2 Fatal or non-fatal MI in PTCA-treated patients on pravastatin or placebo.

View larger version (12K): [in a new window]   Figure 3 Revascularization in PTCA-treated patients on pravastatin or placebo.

View larger version (12K): [in a new window]   Figure 4 Stroke in PTCA-treated patients on pravastatin or placebo.

View larger version (13K): [in a new window]   Figure 5 Primary event rate in CABG-treated patients on pravastatin or placebo.